Compare ACV & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACV | PROF |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 243.2M |
| IPO Year | N/A | 2017 |
| Metric | ACV | PROF |
|---|---|---|
| Price | $26.90 | $6.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 20.8K | ★ 63.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $35.74 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $21.78 | $3.92 |
| 52 Week High | $29.04 | $8.95 |
| Indicator | ACV | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 46.15 |
| Support Level | $26.62 | $6.54 |
| Resistance Level | $28.06 | $7.07 |
| Average True Range (ATR) | 0.67 | 0.29 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 42.83 | 35.67 |
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.